newsfilter
← Latest News
GlobeNewswire·

Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

EDISON, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for